Table 2.
Toxicity | Grade 1 | Grade 2 | Grade 3 | |
---|---|---|---|---|
n (%) | n (%) | n (%) | ||
During treatment, n = 51 |
Dermatitis | 7 (14) | 7 (14) | 3 (6) |
Mucositis | 0 | 0 | 1 (2) | |
Skin reaction(s) | 7 (14) | 6 (12) | 4 (8) | |
Diarrhoea | 8 (16) | 2 (4) | 2 (4) | |
Urinary incontinence/ urinary retention/ Nocturia |
4 (8) | 0 | 0 | |
Dysuria | 3 (6) | 1 (2) | 0 | |
Pyelonephritis | 0 | 1 (2) | 0 | |
Nausea | 1 (2) | 1 (2) | 0 | |
Vomiting | 1 (2) | 0 | 0 | |
Constipation | 0 | 2 (4) | 0 | |
Pain | 1 (2) | 0 | 1 (2) | |
Tiredness/fatigue | 11 (22) | 2 (4) | 0 | |
Appetite loss | 1 (2) | 0 | 0 | |
Three months after treatment, n = 45 |
Skin reaction(s) | 4 (9) | 0 | 0 |
Diarrhoea | 3 (6) | 0 | 0 | |
Urinary incontinence/ urinary retention |
2 (4) | 0 | 0 | |
Dysphagia | 1 (2) | 0 | 0 | |
Nausea | 0 | 0 | 1 (2) | |
Pain | 1 (2) | 1 (2) | 0 | |
Vomiting | 0 | 0 | 1 (2) |